SMS Pharmaceuticals · risk themes across the available quarters.
Bear-case history
Middle East tensions causing sharp increases in solvent costs, which impacted Q4 gross margins on quarter-on-quarter basis. This external factor remains outside management control and could continue to pressure margins if conflict persists.
Single largest customer group accounts for 28% of total revenue across multiple products. Management declined to identify the customer. Concentration risk remains significant if this relationship weakens.
Existing capacity at 80% utilization while expansion is underway creates operational tightness. Any delays in the FY27 brownfield completion could impact volume growth and customer commitments already made for the year.
70% of revenue currently from exports, expected to rise to 75% with new API launches. Currency volatility and geopolitical logistics disruptions create dual exposure to export revenue and raw material imports.